Lymphoma, Leukemia, Hematolymphoid tumors, Pathology, Hematopathology
We aim to better understand tumors of hematolymphoid origin using time-honored (histology) and novel (-omics) technologies.
We are interested in refining our understanding of the clinicopathological characteristics of hematolymphoid tumors in the framework of constantly evolving tumor classifications.
Our tissue biobank includes more than 1000 frozen lymphoma samples, including rare and not well characterized entities.
In the POLAR* Project funded by the LOOP Zurich we aim to characterize the pan-lymphoma proteome and developing a companion biomedical information plattform (BMIP) capable of handling complex multi-omic datasets
